Media headlines about Ovid Therapeutics (NASDAQ:OVID) have trended somewhat positive this week, Accern reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ovid Therapeutics earned a news impact score of 0.05 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.4099851901085 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Ovid Therapeutics (OVID) Upgraded to “Hold” by Zacks Investment Research (americanbankingnews.com)
- Zacks Investment Research Lowers Ovid Therapeutics (OVID) to Sell (americanbankingnews.com)
- Q1 2018 Earnings Estimate for Ovid Therapeutics Issued By Piper Jaffray (OVID) (americanbankingnews.com)
- Ovid Therapeutics (OVID) Upgraded by ValuEngine to Hold (americanbankingnews.com)
- Worthington Industries Net Surges, Synnex Net Tumbles (ticker.com)
Shares of OVID traded down $0.22 during mid-day trading on Friday, hitting $7.99. The company’s stock had a trading volume of 156,514 shares, compared to its average volume of 180,231. The stock has a market capitalization of $196.70 and a P/E ratio of -2.39. Ovid Therapeutics has a fifty-two week low of $5.28 and a fifty-two week high of $15.93.
Several equities analysts have recently issued reports on OVID shares. Zacks Investment Research raised shares of Ovid Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research note on Friday, January 12th. Cowen reaffirmed a “buy” rating on shares of Ovid Therapeutics in a research note on Sunday, April 1st. ValuEngine raised shares of Ovid Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. Finally, Piper Jaffray started coverage on shares of Ovid Therapeutics in a research note on Friday, March 9th. They issued an “overweight” rating and a $20.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $19.50.
Ovid Therapeutics Company Profile
Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate that is in Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome, as well as in preclinical development stage for pediatrics with angelman syndrome.
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.